PuSH - Publikationsserver des Helmholtz Zentrums München

Dannecker, C. ; Wagner, R. ; Peter, A. ; Hummel, J. ; Vosseler, A. ; Häring, H.-U. ; Fritsche, A. ; Birkenfeld, A.L. ; Stefan, N. ; Heni, M.

Low-density lipoprotein cholesterol is associated with insulin secretion.

J. Clin. Endocrinol. Metab. 106, 1576-1584 (2021)
Verlagsversion DOI PMC
Open Access Gold (Paid Option)
Creative Commons Lizenzvertrag
OBJECTIVE: Pharmacological lowering of LDL cholesterol potently reduces cardiovascular risk while concurrently increasing type 2 diabetes risk. The aim of this study was to investigate the relationship between LDL cholesterol concentrations and insulin secretion and glucagon levels. METHODS: 3,039 subjects without cholesterol lowering therapy, but with increased risk for diabetes, underwent routine blood tests and a 5-point oral glucose tolerance test (OGTT). Glucagon concentrations, insulin secretion and insulin clearance indices were derived from the OGTT. RESULTS: There was no association between LDL cholesterol and fasting glucagon (p=0.7, ß=-0.01) or post glucose load glucagon levels (p=0.7, ß=-0.07), but we detected significant positive associations of LDL cholesterol and C-peptide-based indices of insulin secretion (AUCC-Peptide(0-30min)/AUCGlucose(0-30min): p=0.0001, ß=0.06; AUCC-Peptide(0-120min)/AUCGlucose(0-120min): p<0.0001, ß=-0.08). In contrast we found a negative association of insulin-based insulin secretion indices with LDL concentrations (Insulinogenic index: p=0.014, ß=-0.04; disposition index: p=0.0005, ß=-0.06). Though, LDL cholesterol levels were positively associated with insulin clearance assessed from C-peptide and insulin concentrations, both in the fasting state and post glucose load (p<0.0001, ß=0.09 and p<0.0001, ß=0.06, respectively). CONCLUSION: As C-peptide based indices reflect insulin secretion independent of hepatic clearance, our results indicate lower insulin secretion in case of lesser LDL cholesterol. This could explain deteriorating glycemic control in response to cholesterol lowering drugs.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Korrespondenzautor
Schlagwörter Ldl Cholesterol ; Glucagon ; Insulin Clearance ; Insulin Secretion ; Type 2 Diabetes; 14 Randomized-trials; Lowering Therapy; Ldl-cholesterol; Pcsk9; Risk; Metaanalysis; Inhibitors; Clearance; Predictor; Efficacy
ISSN (print) / ISBN 0021-972X
e-ISSN 1945-7197
Zeitschrift Journal of Clinical Endocrinology & Metabolism, The
Quellenangaben Band: 106, Heft: 6, Seiten: 1576-1584 Artikelnummer: , Supplement: ,
Verlag Endocrine Society
Verlagsort Bethesda, Md.
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Diabetes Research and Metabolic Diseases (IDM)
Förderungen Federal Ministry of Education and Research (BMBF)